REFERENCES:
- Owonikoko TK, et al. Soluble FAS ligand as a biomarker of disease
recurrence in differentiated thyroid cancer. Cancer. 2013 Jan 22. doi:
10.1002/cncr.27937.
- Fujimoto K, et al.. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. Oncol Rep. 2011 May;25(5):1211-6.
- Kocsis J, et al. Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis. Cell Stress Chaperones. 2010 Mar;15(2):143-51.
- Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol. 2011 Mar;12(3):286-95. doi: 10.1016/S1470-2045(10)70297-7.
- Tsé C, et al. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012 Apr;38(2):133-42.
- Hewala TI et al. The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3. Pathol Oncol Res. 2012 Oct;18(4):841-8.
- Manivannan P, et al. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian J Biochem Biophys. 2012 Oct;49(5):392-4.
- Nagaraju GP, El-Rayes BF. SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Lett. 2013 Jan 1;328(1):10-7.
- Hurley PJ, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82.
|